Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Neutropenia 1Neoplasms 1Mouth Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Lymphoma, B-Cell, Marginal Zone 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Febrile Neutropenia 1Adenocarcinoma 1

Interventions

Oxaliplatin 19pembrolizumab 13Fluorouracil 12Leucovorin 11Capecitabine 11Paclitaxel 10Gemcitabine 8Docetaxel 8zolbetuximab 6cemiplimab 6Cisplatin 6Albumin-Bound Paclitaxel 6durvalumab 5Ramucirumab 5Radiotherapy 5Irinotecan 4Cyclophosphamide 4130-nm albumin-bound paclitaxel 4trastuzumab deruxtecan 3tislelizumab 3lenvatinib 3enzalutamide 3darolutamide 3Trastuzumab 3Taxes 3S 1 (combination) 3Radiosurgery 3Pemetrexed 3Nivolumab 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Metronidazole × 1 year × Clear all
NCT06616597 2026-02-19

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
58 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡